Vaccine Contract Manufacturing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 – 2027)

The Vaccine Contract Manufacturing Market is segmented by Vaccine Type (Inactivated Vaccines, Live-attenuated Vaccines, RNA Vaccines, Sub-unit Vaccines, and Toxoid-based Vaccines), Process (Downstream (Analytical and QC studies, Fill and Finish Packaging, and Others), Upstream (Bacterial Expression Systems, Baculovirus/Insect Expression Systems, Mammalian Expression Systems, Yeast Expression Systems, and Others)), Scale of Operations (Preclinical, Clinical, and Commercial), End-use (Human Use and Veterinary) and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above-mentioned segments.

Market Snapshot

vaccine contract manufacturing market
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 12.82 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The vaccine contract manufacturing market is projected to register a CAGR of 12.82% during the forecast period (2022 to 2027).

The healthcare system has witnessed enormous challenges as a result of the COVID-19 pandemic. All outpatient treatments were postponed or restricted during the COVID-19 pandemic to ​reduce the risk of viral transmission, as most chronic therapies were regarded as non-urgent. However, with the advent of the COVID-19 infection, large-scale vaccinations were performed all over the world, which majorly benefitted the vaccine contract manufacturing market. An article titled "Capacity Building for Vaccine Manufacturing Across Developing Countries: The Way Forward" published in the journal of Human Vaccines & Immunotherapeutics in January 2022, discussed the aspects of vaccine manufacturing in the developing countries in terms of supply security, control over production scheduling and sustainability, control of costs, socio-economic development, and rapid response to local epidemics. The article indicated that capacity building for manufacturing vaccines in developing countries is of great importance in the COVID-19 period, which is likely to boost the growth of the market in the forecast period.

The initiatives taken by various governments and health organizations all over the world focusing on providing vaccinations to all the people are driving the growth of the vaccine contract manufacturing market in the forecast period. For instance, a February 2020 article by the United Nations Office for the Coordination of Humanitarian Affairs showcased the global measles vaccination drive by Gavi, the Vaccine Alliance, to vaccinate up to 45 million children in seven developing countries. Also, as per the World Health Organization, in February 2022, Djibouti's Ministry of Health, with technical support from WHO and UNICEF, launched a five-day national polio vaccination campaign to vaccinate approximately 150,000 children in Djibouti. These vaccine drives focusing on the preventive measures for various diseases are likely to drive the growth of the market in the study period.

An article titled "Plant-Produced Vaccines: Future Applications in Aquaculture," published in the journal of Frontiers in Plant Science in August 2021, focused on the development of fish vaccines currently utilized and the suitability of the plant-production platform for a fish vaccine. The article indicated that veterinary vaccine production was still lagging behind the development of human vaccines. With the increase in the human population and the food safety demand, aquatic health management is necessary to be addressed. The rise in the development of vaccinations for veterinary animals is also adding to the growth of the market in the forecast period.

In March 2022, Bharat Biotech entered into a partnership with the Spanish biopharmaceutical firm, Biofabri for the development, manufacturing, and marketing of a new tuberculosis vaccine. The new TB vaccine, 'MTBVAC,' is being manufactured and developed by Biofabri in close collaboration with the University of Zaragoza, the International AIDS Vaccine Initiative (IAVI), and the Tuberculosis Vaccine Initiative (TBVI). Such market player activities are also boosting the growth of the vaccine contract manufacturing market in the study period.

The increase in the necessity of vaccine contract manufacturing around the world is expected to propel the growth of the vaccine contract manufacturing market.​ However, the increasing cost of vaccines, along with the lack of storage infrastructure, are hindering the growth of the market in the forecast period.

Scope of the Report

As per the scope of this report, vaccine contract manufacturing is the outsourcing of vaccine production on a large scale to manufacturing units, such as contract manufacturing organizations. The Vaccine Contract Manufacturing Market is segmented by Vaccine Type (Inactivated Vaccines, Live-attenuated Vaccines, RNA Vaccines, Sub-unit Vaccines, and Toxoid-based Vaccines), Process (Downstream (Analytical and QC studies, Fill and Finish, Packaging, and Others), Upstream (Bacterial Expression Systems, Baculovirus/Insect Expression Systems, Mammalian Expression Systems, Yeast Expression Systems, and Others)), Scale of Operations (Preclinical, Clinical, and Commercial), End-use (Human Use and Veterinary) and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa and South America). The Market report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers values (in USD million) for the above-mentioned segments.

By Vaccine Type
Inactivated Vaccines
Live-attenuated Vaccines
RNA Vaccines
Sub-unit Vaccines
Toxoid-based Vaccines
By Process
Downstream
Analytical and QC studies
Fill and Finish
Packaging
Others
Upstream
Bacterial Expression Systems
Baculovirus/Insect Expression Systems
Mammalian Expression Systems
Yeast Expression Systems
Others
By Scale of Operations
Preclinical
Clinical
Commercial
By End-use
Human Use
Veterinary
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Inactivated Vaccines Segment is Expected to Hold a Major Market Share in the Vaccine Contract Manufacturing Market.

The inactivated vaccines hold the major segment in the vaccine contract manufacturing market. Inactivated vaccines are those vaccines that are made from the dead or killed viruses or germs, which are the causative agents of a specific disease.

Various market players have been investing in the research and development of inactivated vaccines for various diseases over the years. An article titled “Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine” published in the journal of Scientific Reports in October 2020 studied the production of an inactivated whole virus vaccine against hepatitis C virus for human use. The article suggested that the higher immunogenicity of whole viruses compared to viral envelope proteins and the historic success of whole virus vaccines makes the whole viruses attractive vaccine antigens. The intricate envelope protein conformation is difficult to replicate in a subunit envelope vaccine. These advantages are expected to propel the growth of the inactivated vaccine segment in the vaccine contract manufacturing market in the forecast period.

Another article presented in the Multi-Disciplinary Publishing Institute journal of Vaccines in November 2021, titled “Development of an Inactivated Vaccine against SARS CoV-2,” discussed the preclinical immunogenicity, protective efficacy, and safety evaluation of a whole-virion inactivated SARS-CoV-2 vaccine candidate (ERUCoV-VAC) to develop a vaccine candidate that recapitulates the severe and fatal progression of COVID-19. The inactivated vaccines have an advantage over the existing SARS-CoV-2 vaccines in that the immune responses to a SARS-CoV-2-inactivated vaccine would target not only the spike protein of SARS-CoV-2 but also other viral proteins, including the matrix, envelope, and nucleocapsid. These advantages of inactivated vaccines and the growing research on vaccine production during the COVID-19 are adding to the growth of the vaccine contract manufacturing market.

According to an article titled “Radiation-Inactivated S. gallinarum Vaccine Provides a High Protective Immune Response by Activating Both Humoral and Cellular Immunity,” published in the journal of Frontiers in Immunology in August 2021, radiation-inactivated serovar Gallinarum can provide a protective immune response similar to the live attenuated 9R vaccine by activating a higher humoral immunity and a lower, but still protective, cellular immune response. The article indicated that radiation-inactivated vaccines provide better efficacy than conventional vaccines. Such research studies favoring the production of inactivated vaccines are adding to the growth of the segment in the studied market.

Several market players are also adding to the growth of the studied market. For instance, in October 2020, Kemin Industries partnered with Pacific GeneTech to launch the first inactivated Eimeria vaccine to the global poultry industry. Such developments in the veterinary inactivated vaccines are likely to boost the scope of the inactivated vaccine segment in the market.

Thus, the rise in the research and development of production of inactivated vaccines and the advantages of inactivated vaccines over conventional vaccine treatments are influencing the growth of the vaccine contract manufacturing market in the forecast period.

Estimated number of cancer cases caused by HPV, United States

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period (2022 – 2027).

The rise in the adoption of highly advanced techniques and systems in the manufacturing of vaccine manufacturing and the technological advancements made in vaccine research and development studies is expected to boost the growth of the market in the North American region. The high awareness among the population on the availability of vaccines in the market contributes to the high market growth in the region.

The rising number of COVID-19 cases in the North American region is adding to the growth of the vaccine contract manufacturing market.​ The large population affected by the SARS-CoV2 infection and the increase in the necessity of vaccine contract manufacturing for the ease of treatment of such infections is expected to propel the growth of the vaccine contract manufacturing market.​ According to the United States Department of Health & Human Services data on Hepatitis B in the region, updated in April 2022, progress toward hepatitis elimination has stalled in recent years. The article indicated that the number of new cases reported estimated number of new cases reported was around 20,700 cases of hepatitis B in 2019. The rise in the number of hepatitis cases in the region requiring adequate vaccines to treat the disease is adding to the growth of the vaccine contract manufacturing market in the region.

In June 2020, the United States Public Health Emergency Declaration released the National Influenza Vaccine Modernization Strategy 2020-2030, which focused on strengthening and diversifying influenza vaccine development, manufacturing, and supply chain. Such activities about the development of novel vaccine therapies are adding to the growth of the studied market.

Also, the increasing healthcare expenditure in the United States is expected to drive the demand for the vaccine contract manufacturing market in this region. According to the United States Centers for Medicare & Medicaid Services National Health Expenditure Data 2020, healthcare expenditure grew from 9.7% to USD 4.1 trillion in 2020 and accounted for around 19.7% of the Gross Domestic Product. The expenditure is projected to reach USD 6.2 trillion by 2028. The rise in the healthcare expenditure in the United States region is likely to boost the growth of the vaccine contract manufacturing market over the forecast period of the study.

Thus the increasing necessity for vaccine contract manufacturing coupled with increasing investment in the health care department is known to propel the growth of the market in this region.

vaccine contract manufacturing market outlook

Competitive Landscape

The vaccine contract manufacturing market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Ajinomoto Bio-Pharma Services, Curia Global, Catalent, Charles River Laboratories International Inc., Cytovance Biologics, and Emergent BioSolutions Inc., and others.

Recent Developments

  • In March 2022, Curia Global entered into a cooperative agreement with the Biomedical Advanced Research and Development Authority (BARDA) and the United States Army Contracting Command to support the domestic production of injectable medicines. The agreement included funding to add a new advanced isolated high-speed fill-finish vial line – which includes biosafety level 2 (BSL-2) containment.
  • In January 2022, Recipharm AB reported a deal with a big pharmaceutical company to support vaccine manufacturing from its facility in Kaysersberg, France. The company is investing almost EUR 14 million into its vaccine manufacturing offering at the site.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and market definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Advancements in Technology and Cost Benefits in Infrastructure and Operational Benefits

      2. 4.2.2 Increase in Initiatives Favouring Vaccinations

      3. 4.2.3 Favorable Patient Demographics & Growing Vaccinations Of Newborns And Children

    3. 4.3 Market Restraints

      1. 4.3.1 Rising High Costs of Vaccines

      2. 4.3.2 Lack of Storage Infrastructure and Limitations Associated with Supply Chain

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value – USD million)

    1. 5.1 By Vaccine Type

      1. 5.1.1 Inactivated Vaccines

      2. 5.1.2 Live-attenuated Vaccines

      3. 5.1.3 RNA Vaccines

      4. 5.1.4 Sub-unit Vaccines

      5. 5.1.5 Toxoid-based Vaccines

    2. 5.2 By Process

      1. 5.2.1 Downstream

        1. 5.2.1.1 Analytical and QC studies

        2. 5.2.1.2 Fill and Finish

        3. 5.2.1.3 Packaging

        4. 5.2.1.4 Others

      2. 5.2.2 Upstream

        1. 5.2.2.1 Bacterial Expression Systems

        2. 5.2.2.2 Baculovirus/Insect Expression Systems

        3. 5.2.2.3 Mammalian Expression Systems

        4. 5.2.2.4 Yeast Expression Systems

        5. 5.2.2.5 Others

    3. 5.3 By Scale of Operations

      1. 5.3.1 Preclinical

      2. 5.3.2 Clinical

      3. 5.3.3 Commercial

    4. 5.4 By End-use

      1. 5.4.1 Human Use

      2. 5.4.2 Veterinary

    5. 5.5 Geography

      1. 5.5.1 North America

        1. 5.5.1.1 United States

        2. 5.5.1.2 Canada

        3. 5.5.1.3 Mexico

      2. 5.5.2 Europe

        1. 5.5.2.1 Germany

        2. 5.5.2.2 United Kingdom

        3. 5.5.2.3 France

        4. 5.5.2.4 Italy

        5. 5.5.2.5 Spain

        6. 5.5.2.6 Rest of Europe

      3. 5.5.3 Asia-Pacific

        1. 5.5.3.1 China

        2. 5.5.3.2 Japan

        3. 5.5.3.3 India

        4. 5.5.3.4 Australia

        5. 5.5.3.5 South Korea

        6. 5.5.3.6 Rest of Asia-Pacific

      4. 5.5.4 Middle-East and Africa

        1. 5.5.4.1 GCC

        2. 5.5.4.2 South Africa

        3. 5.5.4.3 Rest of Middle-East and Africa

      5. 5.5.5 South America

        1. 5.5.5.1 Brazil

        2. 5.5.5.2 Argentina

        3. 5.5.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Ajinomoto Bio-Pharma Services

      2. 6.1.2 Curia Global

      3. 6.1.3 Catalent

      4. 6.1.4 Charles River Laboratories International Inc.

      5. 6.1.5 Cytovance Biologics

      6. 6.1.6 Emergent BioSolutions Inc.

      7. 6.1.7 Fujifilm Holdings

      8. 6.1.8 ICON plc

      9. 6.1.9 IDT Biologika GmbH

      10. 6.1.10 Lonza Group AG

      11. 6.1.11 Recipharm AB

      12. 6.1.12 Richter-Helm BioLogics

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Vaccine Contract Manufacturing Market market is studied from 2019 - 2027.

The Global Vaccine Contract Manufacturing Market is growing at a CAGR of 12.82% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Ajinomoto Bio-Pharma Services, Curia Global, Charles River Laboratories International Inc., Emergent BioSolutions Inc., IDT Biologika GmbH are the major companies operating in Global Vaccine Contract Manufacturing Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!